Identification and Characterization of FTY720 for the Treatment of Human African Trypanosomiasis
View/ Open
File version
Version of Record (VoR)
Author(s)
Jones, Amy J
Kaiser, Marcel
Avery, Vicky M
Griffith University Author(s)
Year published
2016
Metadata
Show full item recordAbstract
The screening of a focused library identified FTY720 (Fingolimod; Gilenya) as a potent selective antitrypanosomal compound active against Trypanosoma brucei gambiense and T. brucei rhodesiense, the causative agents of human African trypanosomiasis (HAT). This is the first report of trypanocidal activity for FTY720, an oral drug registered for the treatment of relapsing multiple sclerosis, and the characterization of sphingolipids as a potential new class of compounds for HAT.The screening of a focused library identified FTY720 (Fingolimod; Gilenya) as a potent selective antitrypanosomal compound active against Trypanosoma brucei gambiense and T. brucei rhodesiense, the causative agents of human African trypanosomiasis (HAT). This is the first report of trypanocidal activity for FTY720, an oral drug registered for the treatment of relapsing multiple sclerosis, and the characterization of sphingolipids as a potential new class of compounds for HAT.
View less >
View less >
Journal Title
Antimicrobial Agents and Chemotherapy
Volume
60
Issue
3
Funder(s)
NHMRC
Grant identifier(s)
APP1067728
Copyright Statement
© 2016 American Society for Microbiology. The attached file is reproduced here in accordance with the copyright policy of the publisher. Please refer to the journal's website for access to the definitive, published version.
Subject
Microbiology
Medical microbiology
Medical microbiology not elsewhere classified
Pharmacology and pharmaceutical sciences